Drugs / Insulin regular
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06592261 | Sep 2024 → Sep 2026 overdue | hyperinsulinism, obesity disorder | Columbia University | Recruiting | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 4 | NCT06036823 Comparator | Oct 2023 → Sep 2025 | mineral metabolism disease | Oman Medical Speciality Board | Completed | No outcome recorded |
| Phase 4 | NCT00795015 Comparator | Apr → Dec 2006 | diabetes mellitus | Rush University Medical Center | Completed | No outcome recorded |
| — | NCT06178874 Comparator | Dec 2023 → May 2024 | glucose metabolism disease | Ain Shams University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Insulin regular | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06178874 ↗ |
| Action | Restore | “replacement of insulin at two different levels (low and high)” NCT06592261 ↗ |
| Route | Intravenous | “IV insulin was administered by continuous infusion” NCT00795015 ↗ |